scholarly journals Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis

2019 ◽  
Vol 1 (1) ◽  
Author(s):  
Arpan R Mehta ◽  
Rachel Walters ◽  
Fergal M Waldron ◽  
Suvankar Pal ◽  
Bhuvaneish T Selvaraj ◽  
...  

Abstract Interventions targeting mitochondrial dysfunction have the potential to extend survival in preclinical models of amyotrophic lateral sclerosis. The aim of this systematic review was to assess the efficacy of targeting mitochondria as a potential therapeutic target in amyotrophic lateral sclerosis. Preclinical studies written in the English language were identified with no restrictions on publication date from PubMed, Medline and EMBASE databases. All studies adopting interventions targeting mitochondria to treat amyotrophic lateral sclerosis in genetic or drug-induced organism models were considered for inclusion. A total of 76 studies were included in the analysis. Survival data were extracted, and the meta-analysis was completed in RevMan 5 software. We show that targeting mitochondrial dysfunction in amyotrophic lateral sclerosis results in a statistically significant improvement in survival (Z = 5.31; P < 0.00001). The timing of administration of the intervention appears to affect the improvement in survival, with the greatest benefit occurring for interventions given prior to disease onset. Interventions at other time points were not significant, although this is likely to be secondary to a lack of publications examining these timepoints. The quality score had no impact on efficacy, and publication bias revealed an overestimation of the effect size, owing to one outlier study; excluding this led to the recalculated effect size changing from 5.31 to 3.31 (P < 0.00001). The extant preclinical literature indicates that targeting mitochondrial dysfunction may prolong survival in amyotrophic lateral sclerosis, particularly if the intervention is administered early. A limitation of current research is a significant bias towards models based on superoxide dismutase 1, with uncertainty about generalisability to amyotrophic lateral sclerosis with an underlying TAR DNA binding protein 43 proteinopathy. However, further mechanistic research is clearly warranted in this field.

2021 ◽  
Author(s):  
Federica Pondrelli ◽  
Lorenzo Muccioli ◽  
Laura Licchetta ◽  
Barbara Mostacci ◽  
Corrado Zenesini ◽  
...  

Objective: To describe the clinical course of Lafora Disease (LD) and identify predictors of outcome by means of a prognostic systematic review with individual participant data meta-analysis. Methods: A search was conducted on MEDLINE and Embase with no restrictions on publication date. Only studies reporting genetically confirmed LD cases were included. Kaplan-Meier estimate was used to assess probability of death and of loss of autonomy. Univariable and multivariable Cox regression models with mixed effects (clustered survival data) were performed to evaluate prognostic factors. Results: Seventy-three papers describing 298 genetically confirmed LD cases were selected. Mean age at disease onset was 13.4 years (SD 3.7), with 9.1% aged≥ 18 years. Overall survival rates in 272 cases were 93% [95% CI 89-96] at 5 years, 62% [95% CI 54-69] at 10 years and 57% [95% CI 49-65] at 15 years. Median survival time was 11 years. The probability of loss of autonomy in 110 cases was 45% [95% CI 36-55] at 5 years, 75% [95% CI 66-84] at 10 years, and 83% [95% CI 74-90] at 15 years. Median loss of autonomy time was 6 years. Asian origin and age at onset <18 years emerged as negative prognostic factors, while type of mutated gene and symptoms at onset were not related to survival or disability. Conclusions: This study documented that half of patients survived at least 11 years. The notion of actual survival rate and prognostic factors is crucial to design studies on the effectiveness of upcoming new disease-modifying therapies.


Author(s):  
Fardin Nabizadeh ◽  
Mohammad Balabandian ◽  
Amir Mohammad Sharafi ◽  
Ali Ghaderi ◽  
Mohammad Reza Rostami ◽  
...  

2017 ◽  
Vol 88 (7) ◽  
pp. 540-549 ◽  
Author(s):  
Zhang-Yu Zou ◽  
Zhi-Rui Zhou ◽  
Chun-Hui Che ◽  
Chang-Yun Liu ◽  
Rao-Li He ◽  
...  

2018 ◽  
Vol 40 (2) ◽  
pp. 235-241 ◽  
Author(s):  
Linting Luo ◽  
Zhibin Song ◽  
Xiaoqiang Li ◽  
Huiwang ◽  
Yaqing Zeng ◽  
...  

2016 ◽  
Vol 3 (2) ◽  
pp. e00023
Author(s):  
J. M. Gregory ◽  
F. M. Waldron ◽  
T. Soane ◽  
L. Fulton ◽  
D. Leighton ◽  
...  

2019 ◽  
Vol 267 (4) ◽  
pp. 944-953 ◽  
Author(s):  
Lu Xu ◽  
Tanxin Liu ◽  
Lili Liu ◽  
Xiaoying Yao ◽  
Lu Chen ◽  
...  

2020 ◽  
Vol 131 (1) ◽  
pp. 106-113 ◽  
Author(s):  
Cláudia S. Silva ◽  
Filipe B. Rodrigues ◽  
Gonçalo S. Duarte ◽  
João Costa ◽  
Mamede de Carvalho

Author(s):  
Joseph Cowling ◽  
Bethany Gorman ◽  
Afrah Riaz ◽  
James R. Bundred ◽  
Sivesh K. Kamarajah ◽  
...  

Abstract Background Many patients with gastric cancer present with late stage disease. Palliative gastrectomy remains a contentious intervention aiming to debulk tumour and prevent or treat complications such as gastric outlet obstruction, perforation and bleeding. Methods We conducted a systematic review of the literature for all papers describing palliative resections for gastric cancer and reporting peri-operative or survival outcomes. Data from peri-operative and survival outcomes were meta-analysed using random effects modelling. Survival data from patients undergoing palliative resections, non-resective surgery and palliative chemotherapy were also combined. This study was registered with the PROSPERO database (CRD42019159136). Results One hundred and twenty-eight papers which included 58,675 patients contributed data. At 1 year, there was a significantly improved survival in patients who underwent palliative gastrectomy when compared to non-resectional surgery and no treatment. At 2 years following treatment, palliative gastrectomy was associated with significantly improved survival compared to chemotherapy only; however, there was no significant improvement in survival compared to patients who underwent non-resectional surgery after 1 year. Palliative resections were associated with higher rates of overall complications versus non-resectional surgery (OR 2.14; 95% CI, 1.34, 3.46; p < 0.001). However, palliative resections were associated with similar peri-operative mortality rates to non-resectional surgery. Conclusion Palliative gastrectomy is associated with a small improvement in survival at 1 year when compared to non-resectional surgery and chemotherapy. However, at 2 and 3 years following treatment, survival benefits are less clear. Any survival benefits come at the expense of increased major and overall complications.


Sign in / Sign up

Export Citation Format

Share Document